Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trans-Golgi network integral membrane protein 2 (TGOLN2)
- Target
- TGOLN2
- Molecular classification
- Integral membrane protein, Resident trans-Golgi network membrane protein, Type I membrane protein
01
Overview
Trans-Golgi network integral membrane protein 2 (TGOLN2) is a type I integral membrane glycoprotein localized to the trans-Golgi network, which functions as a major sorting station for secretory and membrane proteins within eukaryotic cells. TGOLN2 cycles between the trans-Golgi network and early endosomes, playing a key role in vesicular trafficking and exocytic vesicle formation. It is also incorporated as an antigen on the envelope of hepatitis E virus, marking the virus's use of intracellular membranes for assembly. Genetic variants of TGOLN2 have been linked to metastatic patterns in some cancers and are upregulated in certain neuropsychiatric conditions, though causality is undemonstrated. Despite these associations, TGOLN2 is not considered a conventional therapeutic or pharmacological target.
- Other names
- TGN38TGN46TGN48TGN51TTGN2TGN38 homologhTGN46hTGN48hTGN51Trans-Golgi network glycoprotein 46Trans-Golgi network glycoprotein 48Trans-Golgi network glycoprotein 51Trans-Golgi network protein 2TGOLN2
02
Mechanism of action
Not applicable.
03
Biological functions
Membrane traffickingProtein sortingVesicle formation/exocytosisCycles between early endosomes and the trans-Golgi networkMay act as a marker of vesicular membranes for viral budding
04
Disease associations
Cancer (variant associated with non-small cell lung cancer metastasis)Neuropsychiatric/Other brain disorders (upregulation noted in postmortem brain samples from suicide cases)Viral infection (serves as an antigenic marker acquired in the envelope of hepatitis E virus particles)Spastic paraplegia 50, autosomal recessiveOropouche fever (gene-disease association)
05
Safety considerations
None reported. There are no notable therapeutic safety challenges because TGOLN2 is not used as a direct drug target nor are clinical interventions based on its inhibition/activation known.
06
Interacting drugs
None known.
07
Biomarkers
May serve as a marker for vesicular membranes associated with hepatitis E viral particlesVariant rs112065068 may be a prognostic biomarker for distant metastasis in non-small cell lung cancer
Beyond the preview
Go deeper on Trans-Golgi network integral membrane protein 2 (TGOLN2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trans-Golgi network integral membrane protein 2 (TGOLN2).